Table 2.
Five-Year Responses by BCR-ABL1 (IS) Transcript Levels at 3 Months
| Response | % of Patients | |||
|---|---|---|---|---|
| Dasatinib 100 mg Once Daily (n = 259) | Imatinib 400 mg Once Daily (n = 260) | |||
| 3-Month BCR-ABL1 Transcript Level ≤ 10% (n = 198; 84%) | 3-Month BCR-ABL1 Transcript Level > 10% (n = 37; 16%) | 3-Month BCR-ABL1 Transcript Level ≤ 10% (n = 154; 64%) | 3-Month BCR-ABL1 Transcript Level > 10% (n = 85; 36%) | |
| Complete cytogenetic response | 94 | 41 | 92 | 59 |
| Major molecular response | 87 | 38 | 81 | 41 |
| MR4.5 | 54 | 5 | 48 | 12 |
Abbreviations: IS, International Scale; MR4.5, molecular response with a 4.5-log reduction in BCR-ABL1 transcripts from baseline (BCR-ABL1 transcript level ≤ 0.0032% [IS]).